In The News
High Court asked to decide when a judge’s copying and pasting crosses a line
Renegotiated Merivale class action settlement OKd, payout to solicitors, funder cut
Judge facing recusal bid clarifies relationship with litigation funder
Google’s ad tech dominance probed by second class action firm
As money laundering reforms pass, Law Council to keep up calls for exemptions
Virgin wins ACCC approval for alliance with Qatar
AMP class action ‘in search of a case’ after four years, court told
NSW Police can’t appeal ruling on names in strip search class action
Judge OKs cutting edge argument in $900M class action against CBA
Real estate listings giant REA accuses rival Domain of scraping its data
Please login to bookmarkClose

An IP Australia delegate has rejected German drug maker Ever Neuro Pharma’s claim that extensive experimental evidence was needed to prove the usefulness of a Parkinson’s drug developed by UK-based Britannia Pharmaceuticals.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au